Jump to content

DiGeorge syndrome

From Wikipedia, the free encyclopedia
DiGeorge syndrome
Other namesDiGeorge anomaly,[1][2]velocardiofacial syndrome (VCFS),[3]Shprintzen syndrome,[4]conotruncal anomaly face syndrome (CTAF),[5]Takao syndrome,[6]Sedlackova syndrome,[7]Cayler cardiofacial syndrome,[7]CATCH22,[7]22q11.2 deletion syndrome[7]
A child with characteristic facial features of DiGeorge syndrome
SpecialtyMedical genetics
SymptomsVaried; commonlycongenital heart problems,specific facial features,cleft palate[7]
ComplicationsKidney problems,hearing loss,autoimmune disorders[7]
CausesGenetic(typically new mutation)[7]
Diagnostic methodBased on symptoms andgenetic testing[5]
Differential diagnosisSmith–Lemli–Opitz syndrome,Alagille syndrome,VACTERL,Oculo-auriculo-vertebral spectrum[5]
TreatmentInvolves many healthcare specialties[5]
PrognosisDepends on the specific symptoms[3]
Frequency1 in 4,000[7]

DiGeorge syndrome,also known as22q11.2 deletion syndrome,is a syndrome caused by a microdeletion on the long arm ofchromosome 22.[7]While the symptoms can vary, they often includecongenital heart problems,specific facial features, frequent infections,developmental disability,intellectual disabilityandcleft palate.[7]Associated conditions includekidney problems,schizophrenia,hearing lossandautoimmune disorderssuch asrheumatoid arthritisorGraves' disease.[7][8]

DiGeorge syndrome is typically due to the deletion of 30 to 40genesin the middle ofchromosome 22at alocationknown as22q11.2.[3]About 90% of cases occur due to a newmutationduring early development, while 10% areinherited.[7]It isautosomal dominant,meaning that only one affected chromosome is needed for the condition to occur.[7]Diagnosis is suspected based on the symptoms and confirmed bygenetic testing.[5]

Although there is no cure, treatment can improve symptoms.[3]This often includes amultidisciplinaryapproach with efforts to improve the function of the potentially many organ systems involved.[9]Long-term outcomes depend on the symptoms present and the severity of the heart and immune system problems.[3]With treatment, life expectancy may be normal.[10]

DiGeorge syndrome occurs in about 1 in 4,000 people.[7]The syndrome was first described in 1968 by American physicianAngelo DiGeorge.[11][12]In late 1981, the underlying genetics were determined.[12]

Signs and symptoms[edit]

The features of this syndrome vary widely, even among members of the same family, and affect many parts of the body. Characteristic signs and symptoms may include birth defects such as congenital heart disease, defects in the palate, most commonly related to neuromuscular problems with closure (velopharyngeal insufficiency),learning disabilities,mild differences in facial features, and recurrentinfections.Infections are common in children due to problems with theimmune system'sT cell-mediated responsethat in some patients is due to an absent orhypoplasticthymus.DiGeorge syndrome may be first spotted when an affected newborn has heart defects or convulsions fromhypocalcemiadue to malfunctioningparathyroid glandsand low levels of parathyroid hormone (parathormone).[citation needed]

Affected individuals may also have other kinds of birth defects including kidney abnormalities and significant feeding difficulties as babies. Gastrointestinal issues are also very common in this patient population. Digestive motility issues may result in constipation.[13]Disorders such ashypothyroidismandhypoparathyroidismorthrombocytopenia(low platelet levels), andpsychiatricillnesses are common late-occurring features.[14]

Microdeletions in chromosomal region 22q11.2 are associated with a 20 to 30-fold increased risk ofschizophrenia.[15]Studies provide various rates of 22q11.2DS in schizophrenia, ranging from 0.5 to 2.0% and averaging about 1.0%, compared with the overall estimated 0.025% risk of the 22q11.2DS in the general population.[16]

Salient features can be summarized using the mnemonicCATCH-22to describe 22q11.2DS, with the 22 signifying the chromosomal abnormality is found on the 22nd chromosome, as below:[17]

Individuals can have many possible features, ranging in number of associated features and from the mild to the very serious. Symptoms shown to be common include:

This syndrome is characterized byincomplete penetrance.Therefore, there is a marked variability in clinical expression between the different patients. This often makes early diagnosis difficult.[19]

Cognitive impairments[edit]

Children with DiGeorge syndrome have a specific profile in neuropsychological tests. They usually have a below-borderline normal IQ, with most individuals having higher scores in the verbal than the nonverbal domains. Some are able to attend mainstream schools, while others are home-schooled or in special classes. The severity of hypocalcemia early in childhood is associated with autism-like behavioral difficulties.[20]

Adults with DiGeorge syndrome are a specifically high-risk group for developing schizophrenia. About 30% have at least one episode ofpsychosisand about a quarter developschizophreniaby adulthood.[21]

Individuals with DiGeorge syndrome also have a higher risk of developing early onsetParkinson's disease(PD). Diagnosis of Parkinson's can be delayed by up to 10 years due to the use ofantipsychotics,which can cause parkinsonian symptoms.[22][23]

Speech and language[edit]

Current research demonstrates a unique profile of speech and language impairments is associated with 22q11.2DS. Children often perform lower on speech and language evaluations in comparison to their nonverbal IQ scores.[contradictory]Common problems include hypernasality, language delays, and speech sound errors.[24][25][26]

Hypernasalityoccurs when air escapes through the nose during the production of oral speech sounds, resulting in reducedintelligibility.This is a common characteristic in the speech and language profile because 69% of children havepalatalabnormalities. If the structure of the soft palatevelumis such that it does not stop the flow of air from going up to thenasal cavity,it will causehypernasal speech.This phenomenon is referred asvelopharyngeal inadequacy(VPI). Hearing loss can also contribute to increased hypernasality because children with hearing impairments can have difficulty self monitoring their oral speech output. The treatment options available for VPI include prosthesis and surgery.[24][25][27][28][29]

Difficulties acquiring vocabulary and formulating spoken language (expressive languagedeficits) at the onset of language development are also part of the speech and language profile associated with the 22q11.2 deletion.Vocabulary acquisitionis often severely delayed for preschool-age children. In some recent studies, children had a severely limited vocabulary or were still not verbal at 2–3 years of age. School-age children do make progress with expressive language as they mature, but many continue to have delays and demonstrate difficulty when presented with language tasks such as verbally recalling narratives and producing longer and more complex sentences.Receptive language,which is the ability to comprehend, retain, or process spoken language, can also be impaired, although not usually with the same severity as expressive language impairments.[25][28][29][30]

Articulationerrors are commonly present in children with DiGeorge syndrome. These errors include a limited phonemic (speech sound) inventory and the use of compensatory articulation strategies resulting in reduced intelligibility. Thephonemicinventory typically produced consists of sounds made in the front or back of the oral cavity such as:/p/,/w/,/m/,/n/,and glottal stops. Sound made in the middle of the mouth are completely absent. Compensatory articulation errors made by this population of children include:glottal stops,nasal substitutions, pharyngeal fricatives, linguapalatal sibilants, reduced pressure on consonant sounds, or a combination of these symptoms. Of these errors, glottal stops have the highest frequency of occurrence. It is reasoned that a limitedphonemic inventoryand the use of compensatory articulation strategies is present due to the structural abnormalities of the palate. The speech impairments exhibited by this population are more severe during the younger ages and show a trend of gradual improvement as the child matures.[24][28]

Genetics[edit]

DiGeorge syndrome is inherited in anautosomal dominantpattern.

DiGeorge syndrome is caused by aheterozygousdeletion of part of the long arm (q) of chromosome 22, region 1, band 1, sub-band 2 (22q11.2). Approximately 80-90% of patients have a deletion of 3Mband 8% have a deletion of 1.5Mb.[31][32]The number of genes affected by the deletion has been cited as approximately 30 to 50.[33][34]Very rarely, patients with somewhat similar clinical features may have deletions on the short arm of chromosome 10.[35]The disorder has an autosomal dominant inheritance pattern.

A French study of 749 people diagnosed between 1995 and 2013 found that the mutation was inherited in 15% of patients, of which 85.5% was from the mother.[36]Other studies have found inheritance rates of 6–10%. The majority cases are a result of ade novo(new to the family) deletion.[13]This is because the 22q11 region has a structure that makes it highly prone to rearrangements during sperm or egg formation.[37]

The exact mechanism that causes all of the associated features of the syndrome is unknown.[31]Of the 30–50 genes in the deleted region, a number have been identified as possibly playing a role in the development of some of the signs and symptoms.

TBX1[edit]

Haploinsufficiencyof theTBX1gene (T-box transcription factor TBX1) is thought to be the cause of some of the symptoms observed.Point mutationsin this gene have also been observed in individuals with DiGeorge syndrome.[31]TBX1is part of theT-boxfamily of genes which have an important role in tissue and organ formation during embryonic development and it may have a role in the regulation ofdifferentiationof post migrationneural crest cells.The neural crest forms many of the structures affected in DiGeorge syndrome, including the skull bones,mesenchymeof the face and palate, the outflow tract of the heart, and the thymus and parathyroidstroma.When there is a loss of expression ofFGF18during the development of thepharyngeal arches,neural crest cell death is seen. Although neitherFGF18orTBX1is expressed in the neural crest cells,TBX1might have a role in the regulation of FGF18 expression, ensuring that the differentiation of these cells in the pharyngeal region is correct. Therefore, dysfunction ofTBX1may be responsible for some of the symptoms in DiGeorge syndrome.[32]

Research in mouse models has shown that deletion ofTbx1leads to several defects similar to those seen in humans, mainly affecting development of thegreat arteriesand thethymus.[38][39]

The abnormalities seen in the great arteries of mice deficient ofTbx1are a consequence of abnormal formation and remodelling of theaortic archesduring early development. The role ofTbx1for correct formation and remodelling of the aortic arches has been extensively studied in various mouse models suggesting the key role ofTbx1for cardiovascular development and the phenotypes seen in DiGeorge syndrome.

DGCR8[edit]

In mice, haploinsufficiency of theDgcr8gene has been linked to improper regulation of the microRNAmiR-338and 22q11.2 deletion phenotypes.[40]

TANGO2[edit]

Transport and golgi organization 2 homolog (TANGO2) also known as chromosome 22 open reading frame 25 (C22orf25) is a protein that in humans is encoded by theTANGO2gene.[citation needed]

The gene coding for C22orf25 is located on chromosome 22 and the location q11.21, so it is often associated with 22q11.2 deletion syndrome.[41]But with TANGO2 disorder being autosomal recessive, will not occur in all cases.[citation needed]

Mutations in theTANGO2gene may cause defects in mitochondrialβ-oxidation[42]and increasedendoplasmic reticulumstress and a reduction inGolgivolume density.[43]These mutations results in early onsethypoglycemia,hyperammonemia,rhabdomyolysis,cardiac arrhythmias,andencephalopathythat later develops into cognitive impairment.[42][43]

Parkinson's disease genes[edit]

22q11.2DS has been associated with a higher risk of early onsetParkinson's disease(PD). The neuropathology seen is similar toLRRK2-associated PD. None of the genes affected in individuals with 22q11.2DS have previously been linked to PD but there are a number that are likely candidates. These includeDGCR8,which is important for biogenesis of brain microRNA,SEPT5,which encodes a protein that interacts with thePARK2protein,COMT,which is involved in regulating dopamine levels, and microRNA miR-185, which is thought to target known PD locusLRRK2.[22]

Diagnosis[edit]

Result of FISH analysis using LSI probe (TUPLE 1) from DiGeorge/velocardiofacial syndrome critical region. TUPLE 1 (HIRA) probe was labeled in Spectrum Orange andArylsulfatase A(ARSA) in Spectrum Green as control. Absence of the orange signal indicates deletion of the TUPLE 1 locus at 22q11.2.
Brain computer tomography cuts of the person, demonstrating basal ganglia and periventricular calcification[44]

Diagnosis of DiGeorge syndrome can be difficult due to the number of potential symptoms and the variation in phenotypes between individuals. It is suspected in patients with one or more signs of the deletion. In these cases a diagnosis of 22q11.2DS is confirmed by observation of a deletion of part of the long arm (q) of chromosome 22, region 1, band 1, sub-band 2. Genetic analysis is normally performed usingfluorescencein situhybridization(FISH), which is able to detect microdeletions that standard karyotyping (e.g.G-banding) miss. Newer methods of analysis includemultiplex ligation-dependent probe amplificationassay (MLPA) andquantitative polymerase chain reaction(qPCR), both of which can detect atypical deletions in 22q11.2 that are not detected by FISH.[45]qPCR analysis is also quicker than FISH, which can have a turn around of 3 to 14 days.[13]

A 2008 study of a new high-definition MLPA probe developed to detectcopy number variationat 37 points on chromosome 22q found it to be as reliable as FISH in detecting normal 22q11.2 deletions. It was also able to detect smaller atypical deletions that are easily missed using FISH. These factors, along with the lower expense and easier testing mean that this MLPA probe could replace FISH in clinical testing.[46]

Genetic testing using BACs-on-Beads has been successful in detecting deletions consistent with 22q11.2DS during prenatal testing.[47][48]Array-comparative genomic hybridization(array-CGH) uses a large number of probes em Boss ed in a chip to screen the entire genome for deletions or duplications. It can be used in post and pre-natal diagnosis of 22q11.2.[49]

Fewer than 5% of individuals with symptoms of DiGeorge syndrome have normal routine cytogenetic studies and negative FISH testing. In these cases, atypical deletions are the cause.[50]Some cases of 22q11.2 deletion syndrome have defects in other chromosomes, notably a deletion in chromosome region 10p14.[35]

Treatment[edit]

No cure is known for DiGeorge syndrome. Certain individual features are treatable using standard treatments.[51]The key is to identify each of the associated features and manage each using the best available treatments.[citation needed]

For example, in children, it is important that the immune problems are identified early, as special precautions are required regarding blood transfusion and immunization with live vaccines.[52]Thymus transplantationcan be used to address absence of the thymus in the rare, so-called "complete" DiGeorge syndrome.[53]Bacterialinfectionsare treated withantibiotics.Cardiac surgeryis often required for congenital heart abnormalities. Hypoparathyroidism causing hypocalcaemia often requires lifelong vitamin D and calcium supplements. Specialty clinics that provide multi-system care allow for individuals with DiGeorge syndrome to be evaluated for all of their health needs and allow for careful monitoring of the patients. An example of this type of system is the 22q Deletion Clinic atSickKids Hospitalin Toronto, Canada, which provides children with 22q11 deletion syndrome ongoing support, medical care and information from a team of health care workers.[54]

Metirosine(methyltyrosine) is used as an off-label treatment for DiGeorge syndrome.[55]

Epidemiology[edit]

DiGeorge syndrome is estimated to affect between one in 2000 and one in 4000 live births.[56][57]This estimate is based on major birth defects and may be an underestimate, because some individuals with the deletion have few symptoms and may not have been formally diagnosed. It is one of the most common causes ofintellectual disabilitydue to a genetic deletion syndrome.[58]

The number of people affected has been expected to rise because of multiple reasons: (1) surgical and medical advances, an increasing number of people are surviving heart defects associated with the syndrome. These individuals are in turn having children. The chances of a person with DiGeorge syndrome having an affected child is 50% for each pregnancy; (2) Parents who have affected children, but who were unaware of their own genetic conditions, are now being diagnosed as genetic testing become available; (3) Molecular genetics techniques such as FISH (fluorescence in situ hybridization) have limitations and have not been able to detect all 22q11.2 deletions. Newer technologies have been able to detect these atypical deletions.[59]

Etymology[edit]

The signs and symptoms of DiGeorge syndrome are so varied that different groupings of its features were once regarded as separate conditions. These original classifications included velocardiofacial syndrome, Shprintzen syndrome, DiGeorge sequence/syndrome, Sedlackova syndrome, and conotruncal anomaly face syndrome. All are now understood to be presentations of a single syndrome.

ICD-10 2015 version mentions DiGeorge syndrome using two codes: D82.1 (Di George syndrome)[60]and Q93.81 (Velo-cardio-facial syndrome).[61]The ICD-11 Beta Draft discusses the syndrome under “LD50.P1 CATCH 22 phenotype".[61]However, since this syndrome is caused by the deletion of a small piece of chromosome 22, some recommend that the name "22q11.2 deletion syndrome (22q11.2DS)" be used.[62][13]Some experts support changing the name of both DiGeorge and velocardiofacial syndromes to CATCH-22.[citation needed]The International 22q11.2 Foundation, through its "Same Name Campaign", advocates for the name 22q11.2 deletion syndrome.[63]

See also[edit]

References[edit]

  1. ^Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007).Dermatology: 2-Volume Set.St. Louis: Mosby.ISBN978-1-4160-2999-1.
  2. ^James, William D.; Berger, Timothy G.; et al. (2006).Andrews' Diseases of the Skin: clinical Dermatology.Saunders Elsevier.ISBN978-0-7216-2921-6.
  3. ^abcde"22q11.2 deletion syndrome".Genetic and Rare Diseases Information Center (GARD).Archivedfrom the original on 5 July 2017.Retrieved15 May2017.
  4. ^Shprintzen RJ, Goldberg RB, Lewin ML, Sidoti EJ, Berkman MD, Argamaso RV, Young D (January 1978). "A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome".Cleft Palate J.15(1): 56–62.PMID272242.
  5. ^abcde"Chromosome 22q11.2 Deletion Syndrome - NORD (National Organization for Rare Disorders)".NORD (National Organization for Rare Disorders).2017.Archivedfrom the original on 28 January 2017.Retrieved10 July2017.
  6. ^Burn J, Takao A, Wilson D, Cross I, Momma K, Wadey R, Scambler P, Goodship J (October 1993)."Conotruncal anomaly face syndrome is associated with a deletion within chromosome 22q11".J. Med. Genet.30(10): 822–4.doi:10.1136/jmg.30.10.822.PMC1016562.PMID8230157.
  7. ^abcdefghijklmn"22q11.2 deletion syndrome".Genetics Home Reference.July 2013.Archivedfrom the original on 13 May 2017.Retrieved15 May2017.
  8. ^Shah, Anvay; Sinnott, Bridget (2022-02-06)."Newly Diagnosed Hypoparathyroidism as the Initial Presentation of DiGeorge Syndrome in a 26-Year-Old Man".AACE Clinical Case Reports.8(4): 181–182.doi:10.1016/j.aace.2022.02.001.ISSN2376-0605.PMC9363511.PMID35959083.S2CID246664448.
  9. ^Kobrynski LJ, Sullivan KE (October 2007). "Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes".Lancet.370(9596): 1443–52.doi:10.1016/S0140-6736(07)61601-8.PMID17950858.S2CID32595060.
  10. ^Goldman, Lee; Schafer, Andrew I. (2015).Goldman-Cecil Medicine E-Book.Elsevier Health Sciences. p. 702.ISBN9780323322850.Archivedfrom the original on 2017-11-05.
  11. ^DiGeorge, A (1968). "Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism".March of Dimes-Birth Defects Foundation:116–21.
  12. ^abRestivo A, Sarkozy A, Digilio MC, Dallapiccola B, Marino B (February 2006). "22q11 deletion syndrome: a review of some developmental biology aspects of the cardiovascular system".J Cardiovasc Med (Hagerstown).7(2): 77–85.doi:10.2459/01.JCM.0000203848.90267.3e.PMID16645366.S2CID25905258.
  13. ^abcdMcDonald-McGinn DM, Sullivan KE (January 2011)."Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome)".Medicine (Baltimore).90(1): 1–18.doi:10.1097/MD.0b013e3182060469.PMID21200182.S2CID27954882.
  14. ^Debbané M, Glaser B, David MK, Feinstein C, Eliez S (2006). "Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications".Schizophr. Res.84(2–3): 187–93.doi:10.1016/j.schres.2006.01.019.PMID16545541.S2CID9999210.
  15. ^[non-primary source needed]Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R (2003)."The schizophrenia phenotype in 22q11 deletion syndrome".Am J Psychiatry.160(9): 1580–6.doi:10.1176/appi.ajp.160.9.1580.PMC3276594.PMID12944331.
  16. ^[non-primary source needed]Horowitz A, Shifman S, Rivlin N, Pisanté A, Darvasi A (2005). "A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients".Schizophr. Res.73(2–3): 263–7.doi:10.1016/j.schres.2004.02.008.PMID15653270.S2CID40678533.
  17. ^Burn J (October 1999)."Closing time for CATCH22".J. Med. Genet.36(10): 737–8.doi:10.1136/jmg.36.10.737.PMC1734243.PMID10528851.
  18. ^abLindsay EA (November 2001). "Chromosomal microdeletions: dissecting del22q11 syndrome".Nat. Rev. Genet.2(11): 858–68.doi:10.1038/35098574.PMID11715041.S2CID21395147.
  19. ^Swillen A, Vogels A, Devriendt K, Fryns JP (2000). "Chromosome 22q11 deletion syndrome: update and review of the clinical features, cognitive-behavioral spectrum, and psychiatric complications".Am. J. Med. Genet.97(2): 128–35.doi:10.1002/1096-8628(200022)97:2<128::AID-AJMG4>3.0.CO;2-Z.PMID11180220.
  20. ^Muldoon M, Ousley OY, Kobrynski LJ, Patel S, Oster ME, Fernandez-Carriba S, Cubells JF, Coleman K, Pearce BD (September 2015)."The effect of hypocalcemia in early childhood on autism-related social and communication skills in patients with 22q11 deletion syndrome".Eur Arch Psychiatry Clin Neurosci.265(6): 519–24.doi:10.1007/s00406-014-0546-0.PMC4379129.PMID25267002.
  21. ^Zinkstok J, van Amelsvoort T (2005). "Neuropsychological profile and neuroimaging in patients with 22Q11.2 Deletion Syndrome: a review".Child Neuropsychol.11(1): 21–37.doi:10.1080/09297040590911194.PMID15823981.S2CID13520713.
  22. ^abButcher NJ, Kiehl TR, Hazrati LN, Chow EW, Rogaeva E, Lang AE, Bassett AS (2013)."Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications".JAMA Neurol.70(11): 1359–66.doi:10.1001/jamaneurol.2013.3646.PMC4464823.PMID24018986.
  23. ^Mok KY, Sheerin U, Simón-Sánchez J, Salaka A, Chester L, Escott-Price V, et al. (May 2016)."Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data".Lancet Neurol.15(6): 585–96.doi:10.1016/S1474-4422(16)00071-5.PMC4828586.PMID27017469.
  24. ^abcD'Antonio LL, Scherer NJ, Miller LL, Kalbfleisch JH, Bartley JA (2001). "Analysis of speech characteristics in children with velocardiofacial syndrome (VCFS) and children with phenotypic overlap without VCFS".Cleft Palate Craniofac. J.38(5): 455–67.doi:10.1597/1545-1569(2001)038<0455:AOSCIC>2.0.CO;2.ISSN1545-1569.PMID11522167.
  25. ^abcScherer NJ, D'Antonio LL, Kalbfleisch JH (1999)."Early speech and language development in children with velocardiofacial syndrome".Am. J. Med. Genet.88(6): 714–23.doi:10.1002/(SICI)1096-8628(19991215)88:6<714::AID-AJMG24>3.0.CO;2-B.PMID10581495.
  26. ^Scherer NJ, D'Antonio LL, Rodgers JR (2001)."Profiles of communication disorder in children with velocardiofacial syndrome: comparison to children with Down syndrome".Genet. Med.3(1): 72–8.doi:10.1097/00125817-200101000-00016.PMID11339384.
  27. ^Eliez S, Palacio-Espasa F, Spira A (2000). "Young children with Velo-Cardio-Facial syndrome (CATCH-22). Psychological and language phenotypes".Eur Child Adolesc Psychiatry.9(2): 109–14.doi:10.1007/s007870050005.PMID10926060.S2CID12082383.
  28. ^abcRobin NH, Shprintzen RJ (2005). "Defining the clinical spectrum of deletion 22q11.2".J. Pediatr.147(1): 90–6.doi:10.1016/j.jpeds.2005.03.007.PMID16027702.
  29. ^abSolot CB, Knightly C, Handler SD (2000). "Communication disorders in the 22Q11.2 microdeletion syndrome".J Commun Disord.33(3): 187–203, quiz 203–4.doi:10.1016/S0021-9924(00)00018-6.PMID10907715.
  30. ^Persson C, Niklasson L, Oskarsdóttir S, Johansson S, Jönsson R, Söderpalm E (2006). "Language skills in 5-8-year-old children with 22q11 deletion syndrome".Int J Lang Commun Disord.41(3): 313–33.doi:10.1080/13682820500361497.PMID16702096.
  31. ^abcOnline Mendelian Inheritance in Man(OMIM):#188400
  32. ^abPackham EA, Brook JD (April 2003)."T-box genes in human disorders".Hum. Mol. Genet.12 Spec No 1 (90001): R37–44.doi:10.1093/hmg/ddg077.PMID12668595.
  33. ^Tang KL, Antshel KM, Fremont WP, Kates WR (October 2015)."Behavioral and Psychiatric Phenotypes in 22q11.2 Deletion Syndrome".J Dev Behav Pediatr.36(8): 639–50.doi:10.1097/DBP.0000000000000210.PMC4586411.PMID26372046.
  34. ^Maynard TM, Meechan DW, Dudevoir ML, Gopalakrishna D, Peters AZ, Heindel CC, Sugimoto TJ, Wu Y, Lieberman JA, Lamantia AS (November 2008)."Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes".Mol. Cell. Neurosci.39(3): 439–51.doi:10.1016/j.mcn.2008.07.027.PMC2729512.PMID18775783.
  35. ^abBartsch O, Nemecková M, Kocárek E, Wagner A, Puchmajerová A, Poppe M, Ounap K, Goetz P (February 2003). "DiGeorge/velocardiofacial syndrome: FISH studies of chromosomes 22q11 and 10p14, and clinical reports on the proximal 22q11 deletion".Am. J. Med. Genet. A.117A(1): 1–5.doi:10.1002/ajmg.a.10914.PMID12548732.S2CID35570263.
  36. ^Poirsier C, Besseau-Ayasse J, Schluth-Bolard C, Toutain J, Missirian C, Le Caignec C, et al. (June 2016)."A French multicenter study of over 700 patients with 22q11 deletions diagnosed using FISH or aCGH".Eur. J. Hum. Genet.24(6): 844–51.doi:10.1038/ejhg.2015.219.PMC4867458.PMID26508576.
  37. ^Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE (1999). "A common molecular basis for rearrangement disorders on chromosome 22q11".Hum Mol Genet.8(7): 1157–67.doi:10.1093/hmg/8.7.1157.PMID10369860.
  38. ^Jerome LA, Papaioannou VE (March 2001). "DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1".Nat. Genet.27(3): 286–91.doi:10.1038/85845.PMID11242110.S2CID21030663.
  39. ^Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, Pramparo T, Jurecic V, Ogunrinu G, Sutherland HF, Scambler PJ, Bradley A, Baldini A (March 2001). "Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice".Nature.410(6824): 97–101.doi:10.1038/35065105.PMID11242049.S2CID41144744.
  40. ^Chun S, Du F, Westmoreland JJ, Han SB, Wang YD, Eddins D, et al. (January 2017)."Thalamic miR-338-3p mediates auditory thalamocortical disruption and its late onset in models of 22q11.2 microdeletion".Nat. Med.23(1): 39–48.doi:10.1038/nm.4240.PMC5218899.PMID27892953.
  41. ^"TANGO2 transport and golgi organization 2 homolog [Homo sapiens (human)] - Gene - NCBI".ncbi.nlm.nih.gov.
  42. ^abKremer LS, Distelmaier F, Alhaddad B, Hempel M, Iuso A, Küpper C, et al. (2016)."Bi-allelic Truncating Mutations in TANGO2 Cause Infancy-Onset Recurrent Metabolic Crises with Encephalocardiomyopathy".American Journal of Human Genetics.98(2): 358–62.doi:10.1016/j.ajhg.2015.12.009.PMC4746337.PMID26805782.
  43. ^abLalani SR, Liu P, Rosenfeld JA, Watkin LB, Chiang T, Leduc MS, et al. (2016)."Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations".American Journal of Human Genetics.98(2): 347–57.doi:10.1016/j.ajhg.2015.12.008.PMC4746334.PMID26805781.
  44. ^Tonelli AR, Kosuri K, Wei S, Chick D (2007)."Seizures as the first manifestation of chromosome 22q11.2 deletion syndrome in a 40-year old man: a case report".J Med Case Rep.1:167.doi:10.1186/1752-1947-1-167.PMC2222674.PMID18053182.
  45. ^Miller, Kimberley A. (2008). "FISH Diagnosis of 22q11.2 Deletion Syndrome".Newborn and Infant Nursing Reviews.8(1): e11–e19.doi:10.1053/j.nainr.2007.12.006.
  46. ^Jalali GR, Vorstman JA, Errami A, Vijzelaar R, Biegel J, Shaikh T, Emanuel BS (March 2008)."Detailed analysis of 22q11.2 with a high density MLPA probe set".Hum. Mutat.29(3): 433–40.doi:10.1002/humu.20640.PMC2664158.PMID18033723.
  47. ^García-Herrero S, Campos-Galindo I, Martínez-Conejero JA, Serra V, Olmo I, Lara C, Simón C, Rubio C (2014)."BACs-on-Beads technology: a reliable test for rapid detection of aneuploidies and microdeletions in prenatal diagnosis".Biomed Res Int.2014:590298.doi:10.1155/2014/590298.PMC3985206.PMID24795887.
  48. ^Choy KW, Kwok YK, Cheng YK, Wong KM, Wong HK, Leung KO, Suen KW, Adler K, Wang CC, Lau TK, Schermer MJ, Lao TT, Leung TY (September 2014). "Diagnostic accuracy of the BACs-on-Beads™ assay versus karyotyping for prenatal detection of chromosomal abnormalities: a retrospective consecutive case series".BJOG.121(10): 1245–52.doi:10.1111/1471-0528.12873.PMID24893808.S2CID206905761.
  49. ^Park SJ, Jung EH, Ryu RS, Kang HW, Ko JM, Kim HJ, Cheon CK, Hwang SH, Kang HY (May 2011)."Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases".Mol Cytogenet.4:12.doi:10.1186/1755-8166-4-12.PMC3114015.PMID21549014.
  50. ^Mupanemunda, Richard H.; Watkinson, Michael (2004).Key Topics in Neonatology.CRC Press. p. 82.ISBN9781859962343.
  51. ^"DiGeorge syndrome (22q11.2 deletion syndrome)".Mayo Clinic.Retrieved22 May2020.
  52. ^"DiGeorge (22q11.2 deletion) syndrome: Management and prognosis".uptodate.Retrieved2018-10-30.
  53. ^Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, et al. (May 2007)."Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants".Blood.109(10): 4539–47.doi:10.1182/blood-2006-10-048652.PMC1885498.PMID17284531.
  54. ^"Clinical and Metabolic Genetics- The 22q Deletion Clinic".The Hospital for Sick Children.Archivedfrom the original on 2016-04-07.
  55. ^"Doctors said the boy was suffering from teenage psychosis. What he really had was a rare genetic condition".The Washington Post.30 April 2021.
  56. ^Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, et al. (August 2015)."Practical guidelines for managing adults with 22q11.2 deletion syndrome".Genet. Med.17(8): 599–609.doi:10.1038/gim.2014.175.PMC4526275.PMID25569435.
  57. ^Oskarsdóttir S, Vujic M, Fasth A (2004)."Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden".Arch. Dis. Child.89(2): 148–51.doi:10.1136/adc.2003.026880.PMC1719787.PMID14736631.
  58. ^Daily DK, Ardinger HH, Holmes GE (February 2000). "Identification and evaluation of mental retardation".Am Fam Physician.61(4): 1059–67, 1070.PMID10706158.
  59. ^"The Genetics of 22q11.2 DS: Demographics".Information for Medical Professionals.The Dalglish Family Hearts and Minds Clinic for Adults with 22q11.2 Deletion Syndrome.Archivedfrom the original on 9 March 2016.Retrieved26 August2015.
  60. ^"Di George's syndrome".icd10data.2015 ICD-10-CM Diagnosis Code D82.1.Archivedfrom the original on 24 September 2015.Retrieved26 August2015.
  61. ^ab"Velo-cardio-facial syndrome".icd10data.2015 ICD-10-CM Diagnosis Code Q93.81.Archivedfrom the original on 24 September 2015.Retrieved26 August2015.
  62. ^Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, Habel A, Marino B, Oskarsdottir S, Philip N, Sullivan K, Swillen A, Vorstman J (August 2011)."Practical guidelines for managing patients with 22q11.2 deletion syndrome".J. Pediatr.159(2): 332–9.e1.doi:10.1016/j.jpeds.2011.02.039.PMC3197829.PMID21570089.
  63. ^"Same Name Campaign".22q.org.Archivedfrom the original on 2017-06-10.Retrieved2017-06-18.

This article incorporates public domain text fromThe U.S. National Library of Medicine

External links[edit]

Wikimedia Commons has media related toDiGeorge syndrome.
  • McDonald-McGinn DM, Emanuel BS, Zackai EH (December 16, 2005)."22q11.2 Deletion Syndrome".In Pagon RA, Bird TD, Dolan CR, Stephens K (eds.).GeneReviews.University of Washington, Seattle.PMID20301696.NBK1523.
  • Firth HV (February 17, 2009)."22q11.2 Duplication".In Pagon RA, Bird TD, Dolan CR, Stephens K (eds.).GeneReviews.University of Washington, Seattle.PMID20301749.NBK3823.
Retrieved from "https://en.wikipedia.org/w/index.php?title=DiGeorge_syndrome&oldid=1233227644"